Spesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time in patients with various lengths of disease history: Results from the EFFISAYIL® 2 trial. J of Skin. 2024;8(6):s489. doi:10.25251/skin.8.supp.489